Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil

Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland 21231, USA.
AIDS (Impact Factor: 6.56). 08/2007; 21(11):1441-8. DOI: 10.1097/QAD.0b013e328216f441
Source: PubMed

ABSTRACT Tuberculosis is a common complication and leading cause of death in HIV infection. Antiretroviral therapy (ART) lowers the risk of tuberculosis, but may not be sufficient to control HIV-related tuberculosis. Isoniazid preventive therapy (IPT) reduces tuberculosis incidence significantly, but is not widely used.
We analysed tuberculosis incidence in 11 026 HIV-infected patients receiving medical care at 29 public clinics in Rio de Janeiro, Brazil, between 1 September 2003 and 1 September 2005. Data were collected through a retrospective medical record review. We determined rates of tuberculosis in patients who received neither ART nor IPT, only ART, only IPT, or both ART and IPT.
The overall tuberculosis incidence was 2.28 cases/100 person-years (PY) [95% confidence interval (CI) 2.06-2.52]. Among patients who received neither ART nor IPT, incidence was 4.01/100 PY. Patients who received ART had an incidence of 1.90/100 PY (95% CI 1.66-2.17) and those treated with IPT had a rate of 1.27/100 PY (95% CI 0.41-2.95). The incidence among patients who received ART and IPT was 0.80/100 PY (95% CI 0.38-1.47). Multivariate Cox proportional hazards modeling revealed a 76% reduction in tuberculosis risk among patients receiving both ART and IPT (adjusted relative hazard 0.24; P < 0.001) after adjusting for age, previous tuberculosis diagnosis, and CD4 cell counts at baseline.
The use of both IPT and ART in HIV-infected patients is associated with significantly reduced tuberculosis incidence. In conjunction with expanded access to ART, the wider use of IPT in patients with HIV will improve tuberculosis control in high burden areas.

Download full-text


Available from: Valeria Saraceni, Aug 24, 2015
  • Source
    • "These findings are encouraging given the high rates of TB-associated mortality among HIV-infected PWID generally (Corbett et al., 2003; Kourbatova et al., 2006; McShane, 2005; Nunn et al., 2005; Sharma et al., 2005). Recent evidence has demonstrated that utilization of both IPT and ART in HIV-infected patients is associated with reduced TB incidence (Golub et al., 2007; Uyei et al., 2011), and IPT is currently recommended for all HIV-infected patients where TB is prevalent (World Health Organization, 2011). Although patients in the ICL and NCL groups were equally likely to have received recent TB screening, ICL participants were significantly more likely to receive IPT than NCL participants, suggesting that further reductions in morbidity among NCL participants may be achieved in ICL settings. "
    [Show abstract] [Hide abstract]
    ABSTRACT: People who inject drugs (PWID) experience poor outcomes and fuel HIV epidemics in middle-income countries in Eastern Europe and Central Asia. We assess integrated/co-located (ICL) healthcare for HIV-infected PWID, which despite international recommendations, is neither widely available nor empirically examined. A 2010 cross-sectional study randomly sampled 296 HIV-infected opioid-dependent PWID from two representative HIV-endemic regions in Ukraine where ICL, non-co-located (NCL) and harm reduction/outreach (HRO) settings are available. ICL settings provide onsite HIV, addiction, and tuberculosis services, NCLs only treat addiction, and HROs provide counseling, needles/syringes, and referrals, but no opioid substitution therapy (OST). The primary outcome was receipt of quality healthcare, measured using a quality healthcare indicator (QHI) composite score representing percentage of eight guidelines-based recommended indicators met for HIV, addiction and tuberculosis treatment. The secondary outcomes were individual QHIs and health-related quality-of-life (HRQoL). On average, ICL-participants had significantly higher QHI composite scores compared to NCL- and HRO-participants (71.9% versus 54.8% versus 37.0%, p<0.001) even after controlling for potential confounders. Compared to NCL-participants, ICL-participants were significantly more likely to receive antiretroviral therapy (49.5% versus 19.2%, p<0.001), especially if CD4≤200 (93.8% versus 62.5% p<0.05); guideline-recommended OST dosage (57.3% versus 41.4%, p<0.05); and isoniazid preventive therapy (42.3% versus 11.2%, p<0.001). Subjects receiving OST had significantly higher HRQoL than those not receiving it (p<0.001); however, HRQoL did not differ significantly between ICL- and NCL-participants. These findings suggest that OST alone improves quality-of-life, while receiving care in integrated settings collectively and individually improves healthcare quality indicators for PWID.
    Drug and alcohol dependence 09/2013; 134. DOI:10.1016/j.drugalcdep.2013.09.020 · 3.28 Impact Factor
  • Source
    • "Streptomycin based anti-TB therapy which do not contain rifamycin effectively treats TB in HIV patients receiving NNRTIs or nevirapine. Rifapentine can not be used as rifampin substitute (Golub et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tuberculosis is an infection of respiratory tract and Mycobacterium tuberculosis is the causative agent. Multidrug resistance and HIV-coinfection are the burning issues for tuberculosis. The management of drug resistance to tuberculosis is the necessity of the day so by taking effective and controlled measures and giving high doses of 2nd line drugs, we can minimize the death rate in TB. For the HIV-related TB infection, it is necessary to treat TB infection first so that effectiveness of antiretroviral therapy may not be altered and the transmission of M. tuberculosis to other healthy individuals of community could be prevented. All HIV positive individuals who are at a greater risk of acquiring TB infection, either due to suppressed immune system or unhealthy circumstances, must be investigated and if indicated must be treated effectively at immediate basis so that latent TB infection may not progress to active TB.
    Critical Reviews in Microbiology 03/2012; 38(4):267-75. DOI:10.3109/1040841X.2012.664539 · 6.09 Impact Factor
  • Source
    • "Study Setting N Median / Mean Follow-up (Months) Median Baseline CD4 Cell Count (Cells/μL) TB Cncidence, Cases/ 100 PY (Months of ART) Estimated National TB Incidence Rate (Per 100 Population) a High-income countries Girardi et al, 2005 Germany, Switzerland, France, Netherland, UK, Canada, United States 17,142 25.8 280 1.31 (0–3) 0.78 (4–6) 0.46 (7–12) 0.33 (13–24) 0.15 (25–36) 0.005–0.016 Brinkhof et al, 2007 Europe, North America 22,217 11.0 234 1.7 (0–3) 1.0 (4–6) 0.6 (7–12) <0.015 Moreno et al, 2008 Spain 4268 46.0 324 0.5 0.035 Resource-limited settings Badri et al, 2002 South Africa 1034 16.8 254 2.4 0.406 Santoro-Lopes et al, 2002 Brazil 284 22.0 – 8.4 0.071 Lawn et al. 2005 South Africa 346 40.0 242 3.35 (0–12) 1.56 (13–24) 1.36 (25–36) 0.90 (37–48) 1.01 (49–60) 0.576 Seyler et al, 2005 Côte d'Ivoire 129 26.0 125 4.8 0.368 Lawn et al, 2006 South Africa 1002 0.9 96 23.0 (0–3)10.7 (4–6) 7.0 (7–12) 3.7 (13–24) 0.898 Bonnet et al, 2006 Kenya Malawi Cameroon Thailand Cambodia 3151 3.7 6.7 11.1 3.7 7.3 – 17.6 14.3 4.8 10.4 7.6 0.419 0.416 0.194 0.142 – Golub et al, 2007 Brazil 11,026 17.0 – 1.90 0.053 Miranda et al, 2007 Brazil 245 – – 1.2 0.064 Brinkhof et al, 2007 Botswana, Brazil, Côte d'Ivoire, India, Kenya, Nigeria, Malawi, Morocco, Senegal, South Africa, Thailand, Uganda 4540 9.6 107 10.7 (0–3) 7.5 (4–6) 5.2 (7–12) 0.055–0.852 Published as: Clin Chest Med. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Great progress has been made over the past few years in HIV testing in patients who have tuberculosis (TB) and in the scale-up of antiretroviral therapy. More than 3 million people in resource-limited settings were estimated to have started antiretroviral therapy by the end of 2007 and 2 million of these were in sub-Saharan Africa. However, little is known about what impact this massive public health intervention will have on the HIV-associated TB epidemic or how antiretroviral therapy might be used to best effect TB control. This article provides an in-depth review of these issues.
    Clinics in chest medicine 12/2009; 30(4):685-99, viii. DOI:10.1016/j.ccm.2009.08.010 · 2.17 Impact Factor
Show more